Reading EW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EW free→Reading EW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EW free→QuarterlyIQ Insights · EW
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Approval of an amended and restated long-term stock incentive compensation program.
Chief Financial Officer — Theodora Mistras: Edwards Lifesciences Corporation hired Theodora Mistras as the new Chief Financial Officer.
Results of Operations and Financial Condition. On April 23, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the first quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Results of Operations and Financial Condition. On February 10, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as a…
Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart — Larry L. Wood: Larry L. Wood resigned to accept a senior leadership position at another company.
Approval of the amendment and restatement of employee stock purchase plans.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Principal Accounting Officer Retirement and Succession The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024 (the “Retire…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”) announced that Michael A. Mussallem informed the Board of Directors (the “Board”) of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company’s annual meeting of stockholders on May…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'expensive' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.